Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 2128-2135, 2007. First published September 27, 2007; 10.1373/clinchem.2007.092296
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 092296.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.092296v1
53/12/2128    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyauchi, K.
Right arrow Articles by Yamamura, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyauchi, K.
Right arrow Articles by Yamamura, T.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2007;53:2128-2135.)
© 2007 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Development of a Homogeneous Assay to Measure Remnant Lipoprotein Cholesterol

Kazuhito Miyauchi1, Norihiko Kayahara2,a, Masato Ishigami3, Hideyuki Kuwata4, Hideharu Mori4, Hiroyuki Sugiuchi5, Tetsumi Irie6, Akira Tanaka7, Shizuya Yamashita8 and Taku Yamamura3

1 Scientific and Technical Affairs Department, Kyowa Medex Co., Ltd., Tokyo, Japan.
2 Research and Development Department, Kyowa Medex Co., Ltd., Tokyo, Japan.
3 Division of Health Sciences, Osaka University Graduate School of Medicine, Osaka, Japan.
4 Research Laboratory Department, Kyowa Medex Co., Ltd., Shizuoka, Japan.
5 Kumamoto Health Science University, Kumamoto, Japan.
6 Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
7 Laboratory of Clinical Nutrition and Medicine, Kagawa Nutrition University, Saitama, Japan.
8 Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.

aAddress correspondence to this author at: Research and Development Department, Kyowa Medex Co., Ltd., 1-8-10, Harumi, Chuo-ku, Tokyo 104-6004, Japan. Fax 81-3-6219-7614; e-mail norihiko.kayahara{at}kyowa.co.jp.

Background: Quantification of triglyceride-rich lipoprotein (TRL) remnants is useful for risk assessment of coronary artery disease and the diagnosis of type III hyperlipoproteinemia. Although an immunoseparation procedure for remnant-like particle cholesterol has been evaluated extensively in recent years, available methods for measuring TRL remnants have not achieved wide use in routine laboratory practice, suggesting a need for a homogeneous assay that can measure TRL remnant cholesterol in serum or plasma without pretreatment.

Methods: We screened for suitable surfactants that exhibited favorable selectivity toward the VLDL remnant (VLDLR) fraction, including intermediate-density lipoproteins (IDLs). We investigated the principal characteristics of this assay by gel filtration of lipoproteins and their particle size distribution. We developed a simple assay and evaluated its performance with the Hitachi-7170 analyzer.

Results: Polyoxyethylene-polyoxybutylene block copolymer (POE-POB) exhibited favorable selectivity toward VLDLR and IDL fractions. POE-POB removed apolipoprotein (apo) E and apo C-III from IDL particles in the presence of cholesterol esterase (CHER), and the particle size distribution of IDLs became smaller after the reaction. These results revealed that IDL particles are specifically modified in the presence of CHER and POE-POB, making their component cholesterol available for enzymatic assay. Addition of phospholipase D improved the reactivity toward chylomicron remnants (CMRs). We found a high correlation [y = 1.018x– 0.01 mmol/L, r = 0.962 (n = 160)] between the proposed assay and the immunoseparation assay in serum from healthy individuals.

Conclusion: The homogeneous assay described in this report can measure TRL remnant cholesterol, including CMRs, VLDLRs, and IDLs, with high sensitivity and specificity.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
E. J. Schaefer
Limitations of Automated Remnant Lipoprotein Cholesterol Assay for Diagnostic Use
Clin. Chem., November 1, 2009; 55(11): 2061 - 2062.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Ishigami
In Reply
Clin. Chem., November 1, 2009; 55(11): 2062 - 2063.
[Full Text] [PDF]

Home page
 J. Nutr.Home page
E. J. Schaefer, J. A. Gleason, and M. L. Dansinger
Dietary Fructose and Glucose Differentially Affect Lipid and Glucose Homeostasis
J. Nutr., June 1, 2009; 139(6): 1257S - 1262S.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
D. Masuda, K.-i. Hirano, H. Oku, J. C. Sandoval, R. Kawase, M. Yuasa-Kawase, Y. Yamashita, M. Takada, K. Tsubakio-Yamamoto, Y. Tochino, et al.
Chylomicron remnants are increased in the postprandial state in CD36 deficiency
J. Lipid Res., May 1, 2009; 50(5): 999 - 1011.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Lamon-Fava, M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, N. R. Matthan, et al.
Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins
Arterioscler Thromb Vasc Biol, September 1, 2008; 28(9): 1672 - 1678.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.